USANA Health Sciences Inc

USANA Health Sciences Inc(USNA)股票分析

$14.040

-0.060 (-0.43%)收盘时

Loading chart…
High
14.445
Open
14.200
VWAP
14.17
Vol
150.41K
Mkt Cap
867.37M
Low
14.010
Amount
2.13M
EV/EBITDA, TTM
1.21

USANA Health Sciences, Inc. and subsidiaries is a global nutrition, personal health and wellness company that develops and manufactures nutritional supplements, functional foods and personal care products. Its segments include Core nutritional and Hiya direct-to-consumer. The Core nutritional segment develops and manufactures science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness in various geographic markets worldwide that are distributed through the core nutritional channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the United States that are distributed through the direct-to-consumer channel. Its product line includes USANA Nutritionals Optimizers, Essentials/CellSentials, Foods, Personal care and Skincare, and All other. USANA Nutritionals Optimizers products include Proflavanol, CoQuinone 30, and BiOmega-3.

www.usana.com

AI analysis of USANA Health Sciences Inc (USNA)

sell

USANA Health Sciences Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The current price is $14.04, and the company reported a significant earnings miss with an adjusted EPS of -$0.07 compared to expectations of $0.43. Additionally, the forward P/E ratio is 12.55, indicating that the stock may not be undervalued despite its current low price, while the recent news highlights a 5.3% year-over-year revenue decline, which raises concerns about future growth.

Analyst Ratings (2)

+177.78% upside
Buy
2 Buy
0 Hold
0 Sell
Current: 14.04
最低
39.00
平均
39.00
最高
39.00

DA Davidson

2025-02-27

目标价

$36

Hold

DA Davidson

2025-01-02

目标价

$38

Hold

DA Davidson

2024-10-23

目标价

$35

Hold

DA Davidson

2024-07-25

目标价

$38

Hold

DA Davidson

2024-05-07

目标价

$46

Hold

估值指标

The current forward P/E ratio for USANA Health Sciences Inc (USNA) is 12.55, compared to its 5-year average forward P/E of 16.75.

Forward P/E

Fair
5Y Average P/E
16.75
Current P/E
12.55
高估
21.33
低估
12.17

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
5.80
Current EV/EBITDA
1.21
高估
8.62
低估
2.99

Forward P/S

Undervalued
5Y Average P/S
0.99
Current P/S
0.27
高估
1.43
低估
0.55

Alphio AI Price Scenarios for USNA

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%USNA

$29.50

情景价格

B

Base

Base · 50%USNA

$27.07

情景价格

B

Bear

Bear · 25%USNA

$26.51

情景价格

Whales holding USNA

N

Nantahala Capital Management, LLC

+ HoldingUSNA

+9.23%

3M Return

事件时间线

2026-08-04 (ET)

16:30:00

USANA Q2 Revenue $223M, Below Expectations

16:30:00

Lowers Revenue Outlook to $910M

2026-07-20 (ET)

07:30:00

USANA Renews Partnership with Nordiq Canada

2026-05-05 (ET)

16:40:00

Company Projects FY26 Revenue of $925M to $1B

16:40:00

USANA Reports Flat Q1 Revenue of $250M

资讯

USNA FAQ — answered by Alphio AI

USANA Health Sciences, Inc. and subsidiaries is a global nutrition, personal health and wellness company that develops and manufactures nutritional supplements, functional foods and personal care products. Its segments include Core nutritional and Hiya direct-to-consumer. The Core nutritional segment develops and manufactures science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness in various geographic markets worldwide that are distributed through the core nutritional channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the United States that are distributed through the direct-to-consumer channel. Its product line includes USANA Nutritionals Optimizers, Essentials/CellSentials, Foods, Personal care and Skincare, and All other. USANA Nutritionals Optimizers products include Proflavanol, CoQuinone 30, and BiOmega-3. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

USANA Health Sciences Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The current price is $14.04, and the company reported a significant earnings miss with an adjusted EPS of -$0.07 compared to expectations of $0.43. Additionally, the forward P/E ratio is 12.55, indicating that the stock may not be undervalued despite its current low price, while the recent news highlights a 5.3% year-over-year revenue decline, which raises concerns about future growth.

2 analysts cover USNA: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 39.00.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始